Peroxisome Proliferator-activated Receptor γ Induces a Phenotypic Switch from Activated to Quiescent Hepatic Stellate Cells
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Depletion of peroxisome proliferator-activated receptor gamma (PPARgamma) accompanies myofibroblastic transdifferentiation of hepatic stellate cells (HSC), the primary cellular event underlying liver fibrogenesis. The treatment of activated HSC in vitro or in vivo with synthetic PPARgamma ligands suppresses the fibrogenic activity of HSC. However, it is uncertain whether PPARgamma is indeed a molecular target of this effect, because the ligands are also known to have receptor-independent actions. To test this question, the present study examined the effects of forced expression of PPARgamma via an adenoviral vector on morphologic and biochemical features of culture-activated HSC. The vector-mediated expression of PPARgamma itself is sufficient to reverse the morphology of activated HSC to the quiescent phenotype with retracted cytoplasm, prominent dendritic processes, reduced stress fibers, and accumulation of retinyl palmitate. These effects are abrogated by concomitant expression of a dominant negative mutant of PPARgamma that prevents transactivation of but not binding to the PPAR response element. PPARgamma expression also inhibits the activation markers such as the expression of alpha-smooth muscle actin, type I collagen, and transforming growth factor beta1; DNA synthesis; and JunD binding to the activator protein-1 (AP-1) site and AP-1 promoter activity. Inhibited JunD activity by PPARgamma is not due to reduced JunD expression or JNK activity or to a competition for p300. But it is due to a JunD-PPARgamma interaction as demonstrated by co-immunoprecipitation and glutathione S-transferase pull-down analysis. Further, the use of deletion constructs reveals that the DNA binding region of PPARgamma is the JunD interaction domain. In summary, our results demonstrate that the restoration of PPARgamma reverses the activated HSC to the quiescent phenotype and suppresses AP-1 activity via a physical interaction between PPARgamma and JunD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“HSC activation is therefore associated with low levels of PPAR-γ expression, and the assumed relation between PPAR-γ and liver fibrosis was confirmed in an experimental restoration of PPAR-γ levels in HSCs, which resulted in a regression of aHSCs to quiescence state.[126,127]”
From Nuclear receptors in liver fibrosis (2021) · cites this paper as [127]
Citations
Cites
1 retracted
Cytokines suppress adipogenesis and PPAR-γ function through the TAK1/TAB1/NIK cascade
Suzawa, M., Takada, I., Yanagisawa, J., Ohtake, F., Ogawa, S., Yamauchi, T., Kadowaki, T., Takeuchi, Y., Shibuya, H., Gotoh, Y., et al. (2003) · Nature Cell Biology · doi:10.1038/ncb942 · Cited by 292
RetractedAdipogenesis and Obesity: Rounding Out the Big Picture
Spiegelman, B. M., & Flier, J. S. (1996) · Cell · doi:10.1016/s0092-8674(00)81359-8 · Cited by 1,269
Chawla, A., Barak, Y., Nagy, L., Liao, D., Tontonoz, P., & Evans, R. M. (2001) · Nature Medicine · doi:10.1038/83336 · Cited by 1,069
15-Deoxy-Δ 12,14 -prostaglandin J 2 inhibits multiple steps in the NF-κB signaling pathway
Straus, D. S., Pascual, G., Li, M., Welch, J. S., Ricote, M., Hsiang, C.-H., Sengchanthalangsy, L. L., Ghosh, G., & Glass, C. K. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.9.4844 · Cited by 1,004
Peroxisome proliferator-activated receptors and hepatic stellate cell activation
Miyahara, T., Schrum, L., Rippe, R., Xiong, S., Yee, H. F., Motomura, K., Anania, F. A., Willson, T. M., & Tsukamoto, H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m006577200 · Cited by 473
Self-citationGalli, A., Crabb, D. W., Ceni, E., Salzano, R., Mello, T., Svegliati–Baroni, G., Ridolfi, F., Trozzi, L., Surrenti, C., & Casini, A. (2002) · Gastroenterology · doi:10.1053/gast.2002.33666 · Cited by 440
Bissell, D. M., Wang, S. S., Jarnagin, W. R., & Roll, F. J. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118055 · Cited by 419
Marra, F., Efsen, E., Romanelli, R. G., Caligiuri, A., Pastacaldi, S., Batignani, G., Bonacchi, A., Caporale, R., Laffi, G., Pinzani, M., et al. (2000) · Gastroenterology · doi:10.1053/gast.2000.9365 · Cited by 409
Janknecht, R., & Hunter, T. (1996) · Nature · doi:10.1038/383022a0 · Cited by 393
Saxena, N. K., Ikeda, K., Rockey, D. C., Friedman, S. L., & Anania, F. A. (2002) · Hepatology · doi:10.1053/jhep.2002.32029 · Cited by 382
Research works printed but not linked: 8
- Kojima, 2000, Blood, 95, 1309
- Buck, 2000, Am. J. Physiol., 278, G321
- Hellerbrand, 1998, Am. J. Physiol., 275, G269
- Tsukamoto, 1996, Am. J. Physiol., 270, G581
- Xiong, 2001, Hepatology, 34, 520A
- Friedman, 1993, Am. J. Physiol., 264, G947
- Gressner, 1996, Kidney Int. Suppl., 54, S39
- Salbert, 1993, Mol. Endocrinol., 7, 1347
Cited by
Items 201–300 of 327
Prevention of in vitro hepatic stellate cells activation by the adenosine derivative compound IFC305
Velasco-Loyden, G., Pérez‐Carreón, J. I., Agüero, J. F. C., Romero, P. C., Vidrio, S., Martínez-Pérez, L., Yañez-Maldonado, L., Hernández-Muñoz, R. E., Macías‐Silva, M., & de Sánchez, V. C. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.08.017 · Cited by 22
NHE1 deficiency in liver: Implications for non-alcoholic fatty liver disease
Prasad, V., Chirra, S., Kohli, R., & Shull, G. E. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.06.095 · Cited by 22
Roh, Y. J., Kim, H., & Choi, D. W. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0195 · Cited by 23
Mahmoudi, A. A., Atkin, S. L., Jamialahmadi, T., Banach, M., & Sahebkar, A. (2022) · Nutrients · doi:10.3390/nu14204344 · Cited by 21
Mondal, S. A., Sathiaseelan, R., Mann, S. N., Kamal, M., Luo, W., Saccon, T. D., Isola, J. V. V., Peelor, F. F., Li, T., Freeman, W. M., et al. (2022) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00256.2022 · Cited by 21
AQP3 is regulated by PPARγ and JNK in hepatic stellate cells carrying PNPLA3 I148M
Tardelli, M., Bruschi, F. V., Claudel, T., Moreno‐Viedma, V., Halilbasic, E., Marra, F., Herac, M., Stulnig, T. M., & Trauner, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-14557-9 · Cited by 20
Xu, J., Wang, X., Su, G., Yue, J., Sun, Y., Cao, J., Zhang, X., & Zhao, Y. (2018) · Journal of Functional Foods · doi:10.1016/j.jff.2018.05.031 · Cited by 20
Non-coding RNA crosstalk with nuclear receptors in liver disease
Wu, J., Nagy, L. E., Liangpunsakul, S., & Wang, L. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166083 · Cited by 22
Wu, T.-H., Wang, P., Lin, T.-Y., Yang, P., Li, W., Yeh, C., & Pan, T. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112284 · Cited by 20
Rojkind, M., & Reyes‐Gordillo, K. (2009) · Wiley eBooks · doi:10.1002/9780470747919.ch28 · Cited by 21
Hepatic stellate cells and alcoholic liver disease
Vera, M., & Nieto, N. (2006) · Revista Española de Enfermedades Digestivas · doi:10.4321/s1130-01082006000900005 · Cited by 26
Sinha, S., Aizawa, S., Nakano, Y., Rialdi, A., Choi, H. Y., Shrestha, R., Pan, S. Q., Chen, Y., Li, M., Kapelanski‐Lamoureux, A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38406-8 · Cited by 19
Self-citationZhou, Y., Jia, X., Zhou, M., & Liu, J. (2009) · Life Sciences · doi:10.1016/j.lfs.2009.01.018 · Cited by 20
The Role of PPARγ in Hepatocellular Carcinoma
Borbath, I., & Horsmans, Y. (2008) · PPAR Research · doi:10.1155/2008/209520 · Cited by 25
Extracellular Vesicles in Liver Diseases: Meeting Report from the International Liver Congress 2018
Bañales, J. M., Feldstein, A. E., Sänger, H., Lukacs‐Kornek, V., Szabó, G., & Kornek, M. (2019) · Hepatology Communications · doi:10.1002/hep4.1300 · Cited by 19
Elias, M. D. B., de Oliveira, F. L., Guma, F. T. C. R., Martucci, R. B., Borojević, R., & Teodoro, A. J. (2019) · Food & Function · doi:10.1039/c8fo02369g · Cited by 20
Novel targeted therapies for the management of liver fibrosis
Trivella, J. P., Martin, P. B., & Carrion, A. F. (2020) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2020.1735350 · Cited by 22
Guo, Y., Leng, X.-S., Li, T., Peng, J.-R., Song, S., Xiong, L.-F., & Qin, Z.-Z. (2005) · World Journal of Gastroenterology · doi:10.3748/wjg.v11.i30.4735 · Cited by 21
Min, Y., Zhang, Y., Ji, Y. Q., Liu, S., Guan, C., Wei, L., Yu, H., & Zhang, Z. (2025) · Cell & Bioscience · doi:10.1186/s13578-025-01411-z · Cited by 19
Lemoine, M., Serfaty, L., Cervera, P., Capeau, J., & Ratziu, V. (2013) · Hepatology Research · doi:10.1111/hepr.12244 · Cited by 19
Ramani, K., & Tomasi, M. L. (2012) · Hepatology · doi:10.1002/hep.25594 · Cited by 19
Stellate Cells and Hepatic Fibrosis
Hasegawa, D., Wallace, M. C., & Friedman, S. L. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800134-9.00004-x · Cited by 21
Albumin expression is required for adipocyte differentiation of 3T3-L1 cells
Yoo, W., Lee, J., Park, S., Kim, Y., Lim, C., Yoon, E., Hur, G. M., & Oh, J. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.05.067 · Cited by 17
Tai, C., Choong, C.-Y., Lin, Y.-C., Shi, Y.-C., & Tai, C.-J. (2016) · Food & Function · doi:10.1039/c6fo00117c · Cited by 18
Epigenetic Aspects and Prospects in Autoimmune Hepatitis
Czaja, A. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.921765 · Cited by 18
Lee, J. I., Paik, Y., Lee, K. S., Lee, J. W., Kim, Y., Jeong, S. W., Kwon, K. S., Lee, D. H., Kim, H. G., Shin, Y. W., et al. (2007) · Histochemistry and Cell Biology · doi:10.1007/s00418-007-0282-x · Cited by 16
“change of activated HSC into a quiescent form (Hazra et al. 2004), and the very same results could be duplicated using PPAR- ligands.”
ResultEpimorphin, a morphogenic protein, induces proteases in rodent hepatocytes through NF-κB
Miura, K., Yoshino, R., Hirai, Y., Goto, T., Ohshima, S., Mikami, K., Yoneyama, K., Watanabe, D., Sato, M., Senoo, H., et al. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.07.024 · Cited by 16
Epigenetic Effects of an Adenosine Derivative in a Wistar Rat Model of Liver Cirrhosis
Rodríguez‐Aguilera, J. R., Guerrero‐Hernández, C., Pérez‐Molina, R., del Castillo, C. E. C., de Vaca, R. P., Guerrero‐Celis, N., Domínguez, M., Murillo‐de‐Ozores, A. R., Arzate‐Mejía, R. G., Targa, F. R., et al. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26192 · Cited by 15
“In this context, it has been described that PPARg is necessary to revert activated HSCs to a quiescent state, and inhibit the expression of collagen I, TGFb, and aSMA in HSCs [Hazra et al., 2004b; Tsuchida and Friedman, 2017].”
BackgroundMechanistic insights into the effects of SREBP1c on hepatic stellate cell and liver fibrosis
Su, S., Tian, H., Jia, X., Zhu, X., Wu, J., Zhang, Y., Chen, Y., Li, Z., & Zhou, Y. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15614 · Cited by 15
Pioglitazone: The beginning of a new era for NASH?
Serfaty, L. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.03.002 · Cited by 15
Inhibition of Renal Stellate Cell Activation Reduces Renal Fibrosis
Joo, J., Mandal, C., Ghee, J. Y., Yoo, J. A., Lee, M. J., Kang, Y. S., Hyun, Y. Y., Lee, J. E., Kim, H. W., Han, S. Y., et al. (2020) · Biomedicines · doi:10.3390/biomedicines8100431 · Cited by 14
New Approaches for Studying Alcoholic Liver Disease
Xu, J., Liu, X., Gao, B., Karin, M., Tsukamoto, H., Brenner, D. A., & Kisseleva, T. (2014) · Current Pathobiology Reports · doi:10.1007/s40139-014-0053-z · Cited by 13
Self-citationHepatic Fibrosis and Cirrhosis
Rockey, D. C., & Friedman, S. L. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0881-3.00005-x · Cited by 22
Hepatoprotective mechanisms of Yan-gan-wan
Yang, M. D., Deng, Q., CHEN, S., Xiong, S., Koop, D. R., & TSUKAMOTO, H. (2005) · Hepatology Research · doi:10.1016/j.hepres.2005.06.004 · Cited by 13
Self-citationA Role for Peroxisome Proliferator-Activated Receptors in the Immunopathology of Schistosomiasis?
Anthony, B. J., Allen, J., Li, Y. S., & McManus, D. P. (2011) · PPAR Research · doi:10.1155/2012/128068 · Cited by 13
“This downmodulation was associated with increased expression of PPARγ at the gene level as well as with the accumulation of lipid droplets within the cytoplasm of HSCs.”
BackgroundInfluentialEpigenetic mechanism of stellate cell trans-differentiation
Tsukamoto, H. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.11.002 · Cited by 13
“Recent studies highlight the importance of adipogenic regulation in maintenance of HSC quiescence and loss of this regulation in HSC MTD [7–9].”
BackgroundSelf-citationZhou, Y., Li, W., Zhou, J., Chen, J., Wang, X., Cai, M., Li, F.-F., Xu, W. G., Carlsson, P., & Sun, Z. (2019) · Experimental Cell Research · doi:10.1016/j.yexcr.2019.04.012 · Cited by 14
Roles of nuclear receptors in hepatic stellate cells
Pu, S., Zhou, H., Liu, Y., Liu, J., Guo, Y., & Zhou, H. (2021) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2021.1949288 · Cited by 13
Research progress of PPARγ regulation of cholesterol and inflammation in Alzheimer's disease
Gu, L., Ju, Y., Hu, M. S., Miao, Z., Li, Q., & Zhang, X. (2023) · Metabolic Brain Disease · doi:10.1007/s11011-022-01139-6 · Cited by 12
Effects of Dan-shao-hua-xian on expression of PPAR-gamma and NF-kappa B in rat liver fibrosis.
Wang, H.-Y., & Cheng, M.-L. (2008) · PubMed · Cited by 13
Illuminating liver fibrosis with vitamin D
Firrincieli, D., Braescu, T., Housset, C., & Chignard, N. (2013) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2013.10.004 · Cited by 12
“Furthermore, PPAR nhibits human HSC activation in vitro [5], and is able o repress the expression of profibrotic markers in actiated HSCs [6].”
BackgroundThiazolidinediones and hepatic fibrosis: don’t wait too long
Marra, F. (2006) · Gut · doi:10.1136/gut.2005.085399 · Cited by 11
Sun, Y., Yuan, X., Hu, Z., & Li, Y. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116730 · Cited by 10
Jeon, K., Kumar, A., Callan, C. L., DeMagistris, M., Macrae, S. M., Nehrke, K. W., & Huxlin, K. R. (2023) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.64.13.36 · Cited by 10
“TZDs inhibit the fibroblast-to-myofibroblast transition in many tissues, 27–29 including the cornea, 19,20 and have been identified as potential treatments for fibrosis in the liver 30,31 and heart.”
Morphogen-related therapeutic targets for liver fibrosis
Fung, E., & Tsukamoto, H. (2015) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2015.05.017 · Cited by 11
Self-citationPirih, F. Q. M., Abayahoudian, R., Elashoff, D. A., Parhami, F., Nervina, J. M., & Tetradis, S. (2008) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21931 · Cited by 11
“In fact, PPARg’s potency as an adipogenic factor is so strong that an adipogenic phenotype results in several cell types in which PPARg is activated [for recent examples see Hazra et al., 2004; Semple et al., 2006; Singh et al., 2006; Yamanouchi et al., 2007].”
BackgroundKruse, M., Hopf-Jensen, S., Timke, C., Agricola, B., Sparmann, G. H., Schmid, A., Sipos, B., Arlt, A., & Schäfer, H. (2011) · International Journal of Cell Biology · doi:10.1155/2011/816791 · Cited by 10
“In HSC, MDI treatment restored a quiescent phenotype by induction of genes regulating lipid metabolism, an effect also seen by overexpression of PPARγ [26].”
Update on the Treatments of Non-Alcoholic Fatty Liver Disease (NAFLD)
Quercioli, A., Montecucco, F., & Mach, F. (2009) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/1871529x10909040261 · Cited by 11
“[185] Hazra, S.”
BackgroundWang, B., Wu, Z., Li, W., Liu, G., & Tang, Y. (2021) · Chinese Medicine · doi:10.1186/s13020-021-00473-8 · Cited by 9
Anti- and Protumorigenic Effects of PPARγin Lung Cancer Progression: A Double-Edged Sword
Li, H. Y., Weiser‐Evans, M. C. M., & Nemenoff, R. A. (2012) · PPAR Research · doi:10.1155/2012/362085 · Cited by 11
“Similarly, forced expression of PPARγ reversed culture-activated HSCs to a quiescent phenotype [114, 115].”
BackgroundMetabolic reprogramming and cell fate regulation in alcoholic liver disease
Tsukamoto, H. (2015) · Pancreatology · doi:10.1016/j.pan.2015.03.003 · Cited by 10
Self-citationYuan, W., Ahmad, S., & Najar, A. (2017) · PubMed Central · Cited by 9
Ki, M., Lee, H.-R., Park, J., Hong, I., Han, S., You, S., Lee, E.-M., Kim, A.-Y., Lee, S., & Jeong, K. (2010) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2010.04.008 · Cited by 11
“important negative regulator not only of hepatic stellate cells activation [10], but also of inflammation [11].”
BackgroundHepatitis C Virus Infection—Pathobiology and Implications for New Therapeutic Options
Davis, G. L., Krawczynski, K., & Szabó, G. (2007) · Digestive Diseases and Sciences · doi:10.1007/s10620-006-9484-7 · Cited by 10
Effect of ADHI on hepatic stellate cell activation and liver fibrosis in mice
Zhao, T., Han, Z., Zhang, J., Ding, Y., Chen, J., Qiao, H., & Gao, N. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.02.008 · Cited by 8
CILP1 interacting with YBX1 promotes hypertrophic scar formation by suppressing PPARs transcription
Wang, J., Du, J., Song, Y., Tan, X., Wu, J., Wang, T., Shi, Y., Xu, X., Yu, Z., & Song, B. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07554-8 · Cited by 6
Self-citationBeyond hepatic stellate cell heterogeneity: Resolving fibrosis, restoring regeneration (Review)
Gao, C., Chen, G., Jia, H., Zhu, H., Cai, Y., Yang, D., & Zhao, K. (2026) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2026.5733 · Cited by 8
Zhou, Y., Wang, Y., Ni, C., Wang, H., Zhou, J., Wan, B., Li, H., Li, F.-F., Huang, R., Xu, W. G., et al. (2022) · BioMed Research International · doi:10.1155/2022/4581405 · Cited by 6
“Adipogenesis is known as an organized multistep process that requires the sequential activation of many transcription factors, including Ppar γ , which are essential for maintaining stellate cells in their quiescent state [28 – 30].”
Deng, W., Wang, X., Niu, X., Zhang, X., Hou, Y., & Qin, M. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00673 · Cited by 6
Choi, H., Oh, D., Kim, H., Chambugong, M., Kim, M., Lee, M., & Park, H. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122443 · Cited by 7
Ceccherini, E., Cecchettini, A., Morales, M. A., & Rocchiccioli, S. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00813 · Cited by 7
“Other studies have also demonstrated the key role of PPARg expression in the maintenance of the quiescent HSCs phenotype (Hazra et al., June 2020 | Volume 11 | Article 813 2004a; Hazra et al., 2004b).”
BackgroundLian, B., Ren, Y., Zhang, H., Lin, T., & Wang, Y. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109202 · Cited by 6
Lim, J. J., Klaassen, C. D., & Cui, J. Y. (2024) · Drug Metabolism and Disposition · doi:10.1016/j.dmd.2024.100029 · Cited by 6
Lemoine, M., & Serfaty, L. (2011) · La Presse Médicale · doi:10.1016/j.lpm.2011.04.006 · Cited by 5
Interactions of Stellate Cells with Other Non-Parenchymal Cells
Kawada, N., & Parola, M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800134-9.00012-9 · Cited by 8
Molecular and Cellular Aspects of Cirrhosis and How an Adenosine Derivative Could Revert Fibrosis
Rodríguez‐Aguilera, J. R., de Vaca, R. P., Guerrero‐Celis, N., Velasco-Loyden, G., Domínguez-López, M., Targa, F. R., & de Sánchez, V. C. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.83481 · Cited by 5
Chen, J., Huang, X., Huang, Z. L., & Cao, Y. (2022) · Disease Markers · doi:10.1155/2022/9883831 · Cited by 5
RetractedMechanisms of Collagen Network Organization in Response to Tissue/Organ Damage
Saneyasu, T., Yoshioka, S., & Sakai, T. (2016) · InTech eBooks · doi:10.5772/63163 · Cited by 5
Nonalcoholic Fatty Liver Disease
Cheung, O., & Sanyal, A. J. (2010) · Molecular pathology library · doi:10.1007/978-1-4419-7107-4_34 · Cited by 5
Gandhi, C. R. (2010) · Molecular pathology library · doi:10.1007/978-1-4419-7107-4_5 · Cited by 5
Bano, S., Copeland, M. A., Liu, J.-J., Orr, A. V., Stoops, J. W., Mars, W. M., Liu, S., Locker, J. D., Michalopoulos, G. K., & Bhushan, B. (2026) · American Journal Of Pathology · doi:10.1016/j.ajpath.2026.04.015 · Cited by 4
“30,31 Thus, the role of PPAR γ in liver fibrosis is cell type dependent and differs between hepatocyte-targeted and systemic modulation.”
Yu, J., Taylor, L., Rich, C. B., Toselli, P. A., Stone, P., Green, D. S., Warburton, R. R., Hill, N. S., Goldstein, R. H., & POLGAR, P. R. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.22929 · Cited by 4
“The procollagen type 1 has been reported to be visualized as one band when probed by this antibody (Hazra et al., 2004).”
BackgroundHepatic fibrosis: can we treat it clinically?
Das, K., & Chowdhury, A. (2008) · PubMed · Cited by 4
Islam, M. A., Mawya, J., Salma, U., Kasim, N. H. A., & Haque, N. (2025) · World Journal of Stem Cells · doi:10.4252/wjsc.v17.i11.111090 · Cited by 4
Hussain, Z. (2025) · Exploration of Digestive Diseases · doi:10.37349/edd.2025.100563 · Cited by 3
Chen, Z., Yao, Z. Q., Wu, M., Wu, Y., Zhang, J., Liao, Z., Qian, J., Wei, J., Song, L., Yu, L., et al. (2025) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2025.08.014 · Cited by 4
“PPAR γ has been well established as a negative regulator of the TGF β -SMAD2/3 signaling and fibrotic markers [43 – 47].”
PPARα, A Key Regulator of Hepatic Energy Homeostasis in Health and Disease
Leuenberger, N., & Wahli, W. (2009) · Springer eBooks · doi:10.1007/978-3-642-00150-5_20 · Cited by 4
Durairajan, S. S. K., Singh, A. K., & Iyaswamy, A. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i35.3965 · Cited by 5
Baky, N. A. A., Fouad, L. A., Ahmed, K. A., & Alzokaky, A. A. (2024) · Drug and Chemical Toxicology · doi:10.1080/01480545.2024.2358066 · Cited by 2
Proliferation of activated hepatic stellate cells requires REST
Shavva, V. S., Tarnawski, L., Dai, W., Moruzzi, N., Haller, A.-S., Borg, F., Hansson, S., Guo, Q., Cai, M., Fekete, E., et al. (2026) · Molecular Medicine · doi:10.1186/s10020-025-01406-z · Cited by 2
Liver Fibrosis: Current Approaches and Future Directions for Diagnosis and Treatment
Chen, J. Y., Thakar, D., & Chang, T. T. (2018) · Molecular and translational medicine · doi:10.1007/978-3-319-98143-7_15 · Cited by 5
Epigenetics of the pathogenic myofibroblast in lung disease
Bernau, K., Sandbo, N. K., & Brasier, A. R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-823931-5.00018-9 · Cited by 2
An integrated view of liver injury and disease progression in nonalcoholic steatohepatitis
Sanyal, A. J. (2013) · Hepatology International · doi:10.1007/s12072-013-9479-3 · Cited by 2
Cellular and Molecular Pathobiology of Liver Fibrosis and its Pharmacological Intervention
Friedman, S. L. (2007) · Wiley eBooks · doi:10.1002/9780470691861.ch6b · Cited by 2
Wang, S., & Friedman, S. L. (2020) · Hepatology · doi:10.1002/hep.31151 · Cited by 2
“The authors focused on Tcf21, a gene with no previous connection to HSC biology or fibrosis, because glucocorticoid receptor and peroxisome proliferator activated receptor signaling were previously linked to HSC quiescence,(7,8) as were two other transcription factors, GATA binding protein 4 (Gata4) and LIM homeobox 2…”
BackgroundCaon, E., Forlano, R., Mullish, B. H., Manousou, P., & Rombouts, K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95262-0.00025-5 · Cited by 1
Comparison of Different Blockages on the Renin Angiotensin System in Murine Schistosomal Fibrosis.
Ramalho, L. N., Parreira, N. A., Ramalho, F. S., Augusto, M. J., & Rodrigues, V. (2015) · Global Journal of Pathology and Microbiology · doi:10.14205/2310-8703.2014.02.02.4 · Cited by 1
ADVANCES IN TRANSLATIONAL SCIENCE
Sellin, J. H., Murthy, S. K., Goetz, M., Hoffman, A. W., & Kießlich, R. (2012) · Cited by 1
Esteves, E. A., Moreno, L. G., SANTOS, C. D. S., & Ramos, C. L. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99111-7.00015-5 · Cited by 1
Yu, Q., Koda, S., Xu, N., Li, J., Wang, J.-L., Liu, M., Liu, J., Zhang, Y., Yang, H.-M., Zhang, B., et al. (2023) · Current Molecular Medicine · doi:10.2174/1566524023666230418111949 · Cited by 1
Self-citationStone, L. C. (2015) · University of Birmingham Institutional Research Archive (University of Birmingham)
Li, J. (2012) · D-Scholarship@Pitt (University of Pittsburgh)
Ferrer, A. P. (2005) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona)
Activation of Hepatic Stellate Cells: Anti-Adipogenic Differentiation?
Tsukamoto, H. (2006) · Springer eBooks · doi:10.1007/4-431-27174-0_20
“in our laboratory [29].”
BackgroundSelf-citationEpigenetic regulation of hepatic stellate cells and liver fibrosis
Mann, J., & Mann, D. A. (2015) · Wiley eBooks · doi:10.1002/9781118663387.ch31
Vers un traitement médical de la stéatohépatite non alcoolique ?
Louvet, A., & Mathurin, P. (2005) · Gastroentérologie Clinique et Biologique · doi:10.1016/s0399-8320(05)80707-9
Using Stem Cells to Promote Wound Healing: An Emerging Solution for a Clinical Problem
Foster, A. D., & Davis, T. A. (2015) · Stem cell biology and regenerative medicine · doi:10.1007/978-3-319-21702-4_8
Hepatic stellate cell transdifferentiation: Pro-fibrogenic effectors
Lakner, A. M., & NC DOCKS at The University of North Carolina at Charlotte (2011) · NC Digital Online Collection of Knowledge and Scholarship (The University of North Carolina at Greensboro)
Adachi, M., Osawa, Y., Uchinami, H., Kitamura, T., Accili, D., & Brenner, D. A. (2007)
Curcumin in hepatic stellate cell activation in health
Tang, Y. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802972-5.00022-6
Metadata
- Authors
- Hazra, S., Xiong, S., Wang, J., Rippe, R. A., Krishna, V., Chatterjee, K., & Tsukamoto, H.
- Affiliations
- University of Southern California (US)
- University of North Carolina at Chapel Hill (US)
- University of Cambridge (GB)
- Corresponding author
- Tsukamoto, Hidekazu
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2004-03
- Volume
- 279
- Issue
- 12
- Pages
- 11392-11401
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2091296342
- Cited by
- 320
- References
- 38
- Citations by year
- 2026: 12 · 2025: 9 · 2024: 8 · 2023: 12 · 2022: 9 · 2021: 17 · 2020: 15 · 2019: 11 · 2018: 13 · 2017: 17 · 2016: 16 · 2015: 19 · 2014: 11 · 2013: 13 · 2012: 10
- FWCI
- 12.78
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6057 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- U.S. Department of Veterans Affairs (P50AA11999)
- University of Southern California (P30DK48522)
- National Institutes of Health
- National Institute on Alcohol Abuse and Alcoholism (R24 AA12885, P50-AA11999, R37AA006603, R37-AA-06603, R24AA012885, P50AA011999)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30-DK-48522, P30DK048522)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Keywords
- PPARγ, hepatic stellate cells, liver fibrosis, myofibroblast transdifferentiation, JunD, AP-1 transcription factor, PPARγ ligands, retinyl palmitate, alpha-smooth muscle actin, type I collagen, TGF-β1, adenoviral gene transfer
- MeSH terms
- Retinyl Esters, Animals, Binding Sites, Cell Division, Cells, Cultured, Diterpenes, Liver, Male, Phenotype, Transcription Factors, Vitamin A, Polymerase Chain Reaction, Rats, Wistar, DNA, Complementary, Receptors, Cytoplasmic and Nuclear, Transcription Factor AP-1, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.